Other languages Coya Therapeutics, Inc.

Equities

COYA

US22407B1089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
8.21 ^USD	-2.96%		-5.41%	+10.80%

May. 09	Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 20	Chardan Ups PT on Coya Therapeutics to $14 From $11 on Advancements of COYA 302 Targeting Multiple Neurodegenerative Diseases, Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	Mar. 12
Coya Therapeutics Expands Intellectual Property Beyond COYA 302 Product Candidate	Feb. 13
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells in Inflammatory Diseases	Feb. 13
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson?s Disease in Addition to Amyotrophic Lateral Sclerosis	Jan. 16
Coya Therapeutics Expects to File COYA 302 IND Application for ALS in Q2 After 'Successful' FDA Meeting; Shares Rise	Jan. 05
Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral Sclerosis	Jan. 05
Wilbur Ross Joins Coya Therapeutics' Board	Dec. 06
Coya Therapeutics, Inc. and Dr. Reddy's Laboratories SA Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302	Dec. 06
Coya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer?s Disease (AD)	23-10-09
Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis	23-10-05
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis at the 22nd Annual Northeast ALS Consortium Meeting	23-10-03
Coya Therapeutics Secures Global Licensing Rights for CMU's Exosome Engineering Technology	23-09-22
Top Premarket Decliners	23-09-08
Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases	23-09-07
Coya Therapeutics, Inc. Reports the Publication of a Research Article Entitled ?Immunological, Oxidative, and Structural Factors and Their Responses T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis?	23-08-31
Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of Directors	23-08-21
Coya Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Coya Therapeutics, Inc.

Equities

COYA

US22407B1089

Other languages

Filters